BR0015149A - Método e composições para administração de taxanos oralmente a pacientes humanos - Google Patents
Método e composições para administração de taxanos oralmente a pacientes humanosInfo
- Publication number
- BR0015149A BR0015149A BR0015149-1A BR0015149A BR0015149A BR 0015149 A BR0015149 A BR 0015149A BR 0015149 A BR0015149 A BR 0015149A BR 0015149 A BR0015149 A BR 0015149A
- Authority
- BR
- Brazil
- Prior art keywords
- taxane
- human patients
- administered
- compositions
- orally
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 2
- 108010036949 Cyclosporine Proteins 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 238000009101 premedication Methods 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODO E COMPOSIçõES PARA ADMINISTRAçãO DE TAXANOS ORALMENTE A PACIENTES HUMANOS". Agentes antineoplásicos de taxano os quais vinham, até o momento, exibindo biodisponibilidade oral fraca ou não-existente são administrados oralmente a pacientes humanos sofrendo de condições doentias responsivas ao taxano e tornados suficientemente biodisponíveis para atingir níveis terapêuticos no sangue. Em uma concretização preferida, o taxano, de preferência paclitaxel, é co-administrado ao paciente com um agente de intensificação de ciclosporina oral, de preferência ciclosporina A. Por um método preferido, uma dose de intensificador oral é administrada cerca de 0,5-72 horas antes do taxano e uma segunda dose do intensificador é administrada imediatamente antes, junto com ou imediatamente após o taxano. Um método de tratamento de pacientes humanos que sofrem de condições doentias responsivas ao taxano também é proporcionado, bem como um método para proporcionar tal tratamento, ao mesmo tempo em que impede ou reduz as reações de hipersensitividade e alérgicas sem a necessidade de pré-medicação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16231099P | 1999-10-27 | 1999-10-27 | |
| PCT/US2000/029633 WO2001030448A1 (en) | 1999-10-27 | 2000-10-27 | Method and compositions for administering taxanes orally to human patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0015149A true BR0015149A (pt) | 2002-10-29 |
Family
ID=22585092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0015149-1A BR0015149A (pt) | 1999-10-27 | 2000-10-27 | Método e composições para administração de taxanos oralmente a pacientes humanos |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1225956A1 (pt) |
| JP (1) | JP2003512443A (pt) |
| KR (1) | KR20030019296A (pt) |
| CN (1) | CN1450923A (pt) |
| AU (1) | AU1104201A (pt) |
| BR (1) | BR0015149A (pt) |
| CA (1) | CA2389583A1 (pt) |
| CO (1) | CO5251425A1 (pt) |
| CZ (1) | CZ20021484A3 (pt) |
| HU (1) | HUP0203303A3 (pt) |
| IL (1) | IL149360A0 (pt) |
| MX (1) | MXPA02004164A (pt) |
| NO (1) | NO20022008L (pt) |
| PL (1) | PL354777A1 (pt) |
| RU (1) | RU2002113659A (pt) |
| SK (1) | SK5822002A3 (pt) |
| WO (1) | WO2001030448A1 (pt) |
| ZA (1) | ZA200203358B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
| JP2004536026A (ja) | 2000-11-28 | 2004-12-02 | トランスフォーム ファーマシューティカルズ，インコーポレーティッド． | パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤 |
| US20040092428A1 (en) * | 2001-11-27 | 2004-05-13 | Hongming Chen | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
| EP1569620A4 (en) * | 2002-10-30 | 2006-03-22 | Spherics Inc | NANOPARTICULAR BIOACTIVE AGENTS |
| US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
| US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
| PE20060416A1 (es) * | 2004-08-03 | 2006-06-09 | Novartis Ag | Composicion de inhibidores de renina e inhibidores de proteinas de efusion |
| CN101513395B (zh) * | 2008-02-20 | 2011-01-12 | 单宝华 | 紫杉醇类双层软胶囊口服制剂药物 |
| CA2781529C (en) | 2009-09-23 | 2017-10-24 | Indu Javeri | Methods for the preparation of liposomes comprising docetaxel |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| EA027666B1 (ru) | 2010-05-03 | 2017-08-31 | ТЕИКОКУ ФАРМА ЮСЭй, ИНК. | Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| JO3737B1 (ar) * | 2015-07-21 | 2021-01-31 | Athenex Therapeutics Ltd | تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان |
| CN112670147A (zh) * | 2019-10-15 | 2021-04-16 | 北京烁科中科信电子装备有限公司 | 一种利用多磁极磁棒间距控制的自动调节剂量均一性的方法 |
| EP4059497A1 (en) * | 2021-03-17 | 2022-09-21 | Dompé farmaceutici S.p.a. | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| US20240180888A1 (en) * | 2021-03-17 | 2024-06-06 | Dompe' Farmaceutici Spa | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| WO1997027855A1 (en) * | 1996-01-31 | 1997-08-07 | Bristol-Myers Squibb Company | A method of making pharmaceutically active taxanes orally bioavailable |
| US6025359A (en) * | 1996-06-17 | 2000-02-15 | Eli Lilly And Company | Drug resistance and multidrug resistance modulators |
| KR100615783B1 (ko) * | 1997-05-27 | 2006-08-25 | 아이박스 리서치 인코포레이티드 | 탁산 치료를 받고 있는 인체를 제외한 포유동물의 과민증 또는 알러지 반응을 경감시키기 위한 방법 및 약학적 키트 |
| GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| KR100661879B1 (ko) * | 1998-04-01 | 2006-12-27 | 스키에파마 캐나다 인코포레이티드 | 항암 조성물 |
| CA2684454A1 (en) * | 1999-05-21 | 2000-11-18 | American Bioscience, Llc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
-
2000
- 2000-10-27 IL IL14936000A patent/IL149360A0/xx unknown
- 2000-10-27 CA CA002389583A patent/CA2389583A1/en not_active Abandoned
- 2000-10-27 CZ CZ20021484A patent/CZ20021484A3/cs unknown
- 2000-10-27 HU HU0203303A patent/HUP0203303A3/hu unknown
- 2000-10-27 RU RU2002113659/15A patent/RU2002113659A/ru not_active Application Discontinuation
- 2000-10-27 JP JP2001532859A patent/JP2003512443A/ja active Pending
- 2000-10-27 PL PL00354777A patent/PL354777A1/xx not_active Application Discontinuation
- 2000-10-27 MX MXPA02004164A patent/MXPA02004164A/es unknown
- 2000-10-27 KR KR1020027005396A patent/KR20030019296A/ko not_active Withdrawn
- 2000-10-27 CO CO00082131A patent/CO5251425A1/es not_active Application Discontinuation
- 2000-10-27 EP EP00972373A patent/EP1225956A1/en not_active Withdrawn
- 2000-10-27 WO PCT/US2000/029633 patent/WO2001030448A1/en not_active Ceased
- 2000-10-27 CN CN00815924A patent/CN1450923A/zh active Pending
- 2000-10-27 SK SK582-2002A patent/SK5822002A3/sk unknown
- 2000-10-27 AU AU11042/01A patent/AU1104201A/en not_active Abandoned
- 2000-10-27 BR BR0015149-1A patent/BR0015149A/pt not_active IP Right Cessation
-
2002
- 2002-04-26 NO NO20022008A patent/NO20022008L/no not_active Application Discontinuation
- 2002-04-26 ZA ZA200203358A patent/ZA200203358B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0203303A3 (en) | 2005-01-28 |
| CN1450923A (zh) | 2003-10-22 |
| NO20022008D0 (no) | 2002-04-26 |
| SK5822002A3 (en) | 2003-01-09 |
| ZA200203358B (en) | 2003-04-29 |
| AU1104201A (en) | 2001-05-08 |
| CZ20021484A3 (cs) | 2003-12-17 |
| PL354777A1 (en) | 2004-02-23 |
| EP1225956A1 (en) | 2002-07-31 |
| MXPA02004164A (es) | 2002-10-17 |
| WO2001030448A1 (en) | 2001-05-03 |
| NO20022008L (no) | 2002-06-19 |
| RU2002113659A (ru) | 2004-01-27 |
| JP2003512443A (ja) | 2003-04-02 |
| KR20030019296A (ko) | 2003-03-06 |
| CA2389583A1 (en) | 2001-05-03 |
| CO5251425A1 (es) | 2003-02-28 |
| HUP0203303A2 (hu) | 2003-02-28 |
| IL149360A0 (en) | 2002-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0015149A (pt) | Método e composições para administração de taxanos oralmente a pacientes humanos | |
| Picus et al. | Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results | |
| BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
| NO20014842D0 (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
| BRPI0408999A (pt) | comprimidos prensados de multiparticulados de liberação oral prolongada | |
| CA2301057A1 (en) | A method of administering liposomal encapsulated taxane | |
| RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
| NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| HUT60630A (en) | Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature | |
| BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
| BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
| CA2321565C (en) | L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| RU2007138867A (ru) | Режимы дозирования транс-кломифена | |
| ATE454139T1 (de) | Arzneimittel mit shikonin als wirkstoff | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| ATE331523T1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| DE3688787D1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
| BR9917605A (pt) | Composição substituta de plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A,7A E 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/42 (2006.01), A61P 35/00 (2006.01), A61K 3 |